With over 20 years of experience in providing bioservices
to the biotech industry, New Delhi-based BI Biotech is looking forward
to a significant growth in the coming years. In an interview with
BioSpectrum, Vinaya K Dubey, director of sales and marketing, BI
Biotech India, shares his views on the future plans of the company,
segments catered by it and challenges faced by biosuppliers in India.
Which are the services offered by
BI Biotech to the life sciences industry in India?
BI Biotech India was established with an objective of providing high
quality research products that includes consumables and equipments with
excellent customer support and on-time delivery through its
distribution network. The company provides wide range of proteins,
antibodies, ELISA kits, stem cell products, gene array products, siRNA,
transfection reagents and other consumables and instruments for
complete solutions for laboratories working in genomics, proteomics,
cell biology, immunology and drug discovery.
What are the different segments
and customers that the company caters to?
BI Biotech India has a focused strategy for the Indian biotech industry
by initiating major divisions like genomics, proteomics, cell biology,
immunology and healthcare. Our major clients are pharma and CRO
companies including government institutions.
What are the major contributors to
BI Biotech India has registered a revenue growth of 21 percent in
2009-10 and in 2010-11, the company is expected to grow at 30–35
percent. The three fundamentals —value, service and support—are the
major factors that contributed to the success and growth of the company.
What are the key partnerships and
The company has partnerships with some of the world-renowned companies
like Abnova, AnaSpec, Bachem, Bellco Biotechnology, Cedarlane
Laboratories, Global Stem, RayBiotech, R&D Systems, SABiosciences,
and Santa Cruz Biotechnology. These partnerships helped to bring out
comprehensive range of products that fulfills the need of researchers
in the area of specially cell biology.
What are the main challenges as
far as the product supply is concerned?
One of the major challenges faced by biosuppliers in India is the delay
in purchase process that ranges from weeks to several months, which
affects the overall product supply. More importance to price over
quality/technology is also a major obstacle to the purchase process in
How is the opportunity for biotech
industry in India shaping up?
India has the capability to become a world leader in biotech sector in
the coming years. The efforts in this direction have already started so
as to bring the public and private partnerships to a common platform.
Foreseeing the new opportunities, BI Biotech India reviews its strategy
from time to time and strikes new partnerships to tap the business
Does BI Biotech has any plans to
expand its product line?
BI Biotech India is focusing on two major business segments in the
biotech industry—clinical trial market and providing solutions for the
needs of scientists from immunology and cell biology segments. The
company has been entering into new partnerships in the areas of stem
cell and nanotechnology, especially in the healthcare sector.
Rahul Koul in New Delhi